

2020 Opioid Addiction Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

<https://marketpublishers.com/r/2D5E7A3129B9EN.html>

Date: February 2020

Pages: 132

Price: US\$ 1,999.00 (Single User License)

ID: 2D5E7A3129B9EN

Abstracts

The 2020 Opioid Addiction pipeline report presents a comprehensive overview of the research and development of Opioid Addiction drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: Two drugs in Research phase, 23 drugs in pre-clinical phase, nine drugs in Phase 1, IND filed- 1 drug, and three drugs in Phase 2

As of February 2020, the Opioid Addiction pipeline remains robust with 38 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Opioid Addiction treatment. Diverse types of targeted therapies are being explored through clinical trials including Aldehyde dehydrogenase 2 inhibitors; Alpha 2 adrenergic receptor agonists; Alpha3 beta4 nicotinic receptor antagonists; Cannabinoid receptor agonists; CK1 delta and CK1 epsilon inhibitor; dopamine D3 and D2 receptor antagonist; Endothelin A receptor antagonist; gamma-amino butyric acid type B (GABA-B) receptor agonist; MMP Inhibitor; Opiate receptor antagonist; Opioid mu, kappa, delta receptor agonists; Opioid receptor antagonists; orexin receptor type 1 antagonists; PDE7 inhibitors; Peroxisome proliferator-activated receptor gamma agonists; Serotonin 3 receptor antagonists.

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Opioid Addiction drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it

enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

PUBLISHER EXPERTISE

VPAResearch online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

SCOPE:

The report scope comprises of both pre-clinical phase and clinical phase development drugs for Opioid Addiction development

Opioid Addiction pipeline compounds and molecules under study by both large scale and small companies are included in the report

Opioid Addiction pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered

Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered

Further, orphan drug status, fast track designation, different grants awarded and special status for Opioid Addiction pipeline candidates included

Business overview and snapshot of all companies involved in Opioid Addiction pipeline are included

Latest market and pipeline developments are provided in the report

Opium (Opioid) Addiction pipeline companies included in the report are- Adial Pharmaceuticals Inc, Amygdala Neurosciences Inc, Aphios Corp, Aquilus

Pharmaceuticals Inc, BioCorRx Inc, BioDelivery Sciences International Inc, BioXcel Therapeutics Inc, Bridge Therapeutics Inc, C4X Discovery Holdings Plc, Cessation Therapeutics LLC, Delpor Inc, Emerald Bioscience Inc, Indivior Plc, Insys Therapeutics Inc, iX Biopharma Ltd, Mind Medicine Inc, Nirsum Laboratories Inc, Omeros Corp, Opiant Pharmaceuticals Inc, Orexigen Therapeutics Inc, Osmotica Pharmaceutical Corp, Pfizer Inc, Pharmazz Inc, Phoenix PharmaLabs Inc, Plumb Pharmaceuticals LLC, Serina Therapeutics Inc, Titan Pharmaceuticals Inc, Trevena Inc, Viverra Pharmaceuticals Inc, Zynherba Pharmaceuticals Inc

Opium (Opioid) Addiction pipeline drugs profiled in the report include- AD04 (ondansetron), ANS-6637, APH-1501, AQU-010, BICX-101, BICX-102 (Naltrexone), buprenorphine hydrochloride, dexmedetomidine (BXCL501), BT-219, C4X3256, Monoclonal Antibody for Opioid Use Disorder, Anti-Heroin/Fentanyl Vaccine for Opioid Use Disorder, DLP-160 (naltrexone), NB 2111, INDV-6200 (buprenorphine), Buprenorphine/naloxone -Insys, buprenorphine (BnoX), 18-MC, NRS-033, NRS-067, OMS405, OMS527, OPNT003 (Intranasal nalmefene), OPNT005, OPNT006, OREX-1019, OREX-1038, Arbaclofen extended release, PF-4363467, PF-5006739, PMZ-2123, PPL-103, naltrexone extended release, SER-227, nalmefene, TRV734, TM002, naltrexone hydrochloride

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. EXECUTIVE SUMMARY

- 2.1 Report Scope and Research Methodology
- 2.2 Introduction to Opium (Opioid) Addiction Condition
- 2.3 Opium (Opioid) Addiction Pipeline Snapshot, 2020
- 2.4 Companies investing in Opium (Opioid) Addiction pipeline therapeutics
- 2.5 Phase wise Opium (Opioid) Addiction Pipeline Candidates
- 2.6 Most Researched Mechanism of Action of Opium (Opioid) Addiction Pipeline Products
- 2.7 Route of Administration of Opium (Opioid) Addiction Pipeline Drugs

3. COMPANIES ACTIVE IN PIPELINE DEVELOPMENT

- 3.1 Adial Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
- 3.2 Amygdala Neurosciences Inc Overview, Contacts and ASD Pipeline Drugs
- 3.3 Aphios Corp Overview, Contacts and ASD Pipeline Drugs
- 3.4 Aquilus Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
- 3.5 BioCorRx Inc Overview, Contacts and ASD Pipeline Drugs
- 3.6 BioDelivery Sciences International Inc Overview, Contacts and ASD Pipeline Drugs
- 3.7 BioXcel Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
- 3.8 Bridge Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
- 3.9 C4X Discovery Holdings Plc Overview, Contacts and ASD Pipeline Drugs
- 3.10 Cessation Therapeutics LLC Overview, Contacts and ASD Pipeline Drugs
- 3.11 Delpor Inc Overview, Contacts and ASD Pipeline Drugs
- 3.12 Emerald Bioscience Inc Overview, Contacts and ASD Pipeline Drugs
- 3.13 Indivior Plc Overview, Contacts and ASD Pipeline Drugs
- 3.14 Insys Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
- 3.15 iX Biopharma Ltd Overview, Contacts and ASD Pipeline Drugs
- 3.16 Mind Medicine Inc Overview, Contacts and ASD Pipeline Drugs
- 3.17 Nirsum Laboratories Inc Overview, Contacts and ASD Pipeline Drugs
- 3.18 Omeros Corp Overview, Contacts and ASD Pipeline Drugs
- 3.19 Opiant Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs

- 3.20 Orexigen Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
- 3.21 Osmotica Pharmaceutical Corp Overview, Contacts and ASD Pipeline Drugs
- 3.22 Pfizer Inc Overview, Contacts and ASD Pipeline Drugs
- 3.23 Pharmazz Inc Overview, Contacts and ASD Pipeline Drugs
- 3.24 Phoenix PharmaLabs Inc Overview, Contacts and ASD Pipeline Drugs
- 3.25 Plumb Pharmaceuticals LLC Overview, Contacts and ASD Pipeline Drugs
- 3.26 Serina Therapeutics Inc Overview, Contacts and ASD Pipeline Drugs
- 3.27 Titan Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
- 3.28 Trevena Inc Overview, Contacts and ASD Pipeline Drugs
- 3.29 Vivera Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs
- 3.30 Zynerba Pharmaceuticals Inc Overview, Contacts and ASD Pipeline Drugs

4. ACTIVE PIPELINE DRUG DETAILS, 2020

- 4.1 AD04 (ondansetron) Drug Details
 - 4.1.1 AD04 (ondansetron) Current Status
 - 4.1.2 AD04 (ondansetron) Drug Overview
 - 4.1.3 AD04 (ondansetron) Mechanism of Action
 - 4.1.4 AD04 (ondansetron) Licensing/Collaboration Companies
 - 4.1.5 AD04 (ondansetron) Clinical Trials
- 4.2 ANS-6637 Drug Details
 - 4.2.1 ANS-6637 Current Status
 - 4.2.2 ANS-6637 Drug Overview
 - 4.2.3 ANS-6637 Mechanism of Action
 - 4.2.4 ANS-6637 Licensing/Collaboration Companies
 - 4.2.5 ANS-6637 Clinical Trials
- 4.3 APH-1501 Drug Details
 - 4.3.1 APH-1501 Current Status
 - 4.3.2 APH-1501 Drug Overview
 - 4.3.3 APH-1501 Mechanism of Action
 - 4.3.4 APH-1501 Licensing/Collaboration Companies
 - 4.3.5 APH-1501 Clinical Trials
- 4.4 AQU-010 Drug Details
 - 4.4.1 AQU-010 Current Status
 - 4.4.2 AQU-010 Drug Overview
 - 4.4.3 AQU-010 Mechanism of Action
 - 4.4.4 AQU-010 Licensing/Collaboration Companies
 - 4.4.5 AQU-010 Clinical Trials
- 4.5 BICX-101 Drug Details

- 4.5.1 BICX-101 Current Status
- 4.5.2 BICX-101 Drug Overview
- 4.5.3 BICX-101 Mechanism of Action
- 4.5.4 BICX-101 Licensing/Collaboration Companies
- 4.5.5 BICX-101 Clinical Trials
- 4.6 BICX-102 (Naltrexone) Drug Details
 - 4.6.1 BICX-102 (Naltrexone) Current Status
 - 4.6.2 BICX-102 (Naltrexone) Drug Overview
 - 4.6.3 BICX-102 (Naltrexone) Mechanism of Action
 - 4.6.4 BICX-102 (Naltrexone) Licensing/Collaboration Companies
 - 4.6.5 BICX-102 (Naltrexone) Clinical Trials
- 4.7 buprenorphine hydrochloride Drug Details
 - 4.7.1 buprenorphine hydrochloride Current Status
 - 4.7.2 buprenorphine hydrochloride Drug Overview
 - 4.7.3 buprenorphine hydrochloride Mechanism of Action
 - 4.7.4 buprenorphine hydrochloride Licensing/Collaboration Companies
 - 4.7.5 buprenorphine hydrochloride Clinical Trials
- 4.8 dexmedetomidine (BXCL501) Drug Details
 - 4.8.1 dexmedetomidine (BXCL501) Current Status
 - 4.8.2 dexmedetomidine (BXCL501) Drug Overview
 - 4.8.3 dexmedetomidine (BXCL501) Mechanism of Action
 - 4.8.4 dexmedetomidine (BXCL501) Licensing/Collaboration Companies
 - 4.8.5 dexmedetomidine (BXCL501) Clinical Trials
- 4.9 BT-219 Drug Details
 - 4.9.1 BT-219 Current Status
 - 4.9.2 BT-219 Drug Overview
 - 4.9.3 BT-219 Mechanism of Action
 - 4.9.4 BT-219 Licensing/Collaboration Companies
 - 4.9.5 BT-219 Clinical Trials
- 4.10 C4X3256 Drug Details
 - 4.10.1 C4X3256 Current Status
 - 4.10.2 C4X3256 Drug Overview
 - 4.10.3 C4X3256 Mechanism of Action
 - 4.10.4 C4X3256 Licensing/Collaboration Companies
 - 4.10.5 C4X3256 Clinical Trials
- 4.11 Monoclonal Antibody for Opioid Use Disorder Drug Details
 - 4.11.1 Monoclonal Antibody for Opioid Use Disorder Current Status
 - 4.11.2 Monoclonal Antibody for Opioid Use Disorder Drug Overview
 - 4.11.3 Monoclonal Antibody for Opioid Use Disorder Mechanism of Action

- 4.11.4 Monoclonal Antibody for Opioid Use Disorder Licensing/Collaboration Companies
 - 4.11.5 Monoclonal Antibody for Opioid Use Disorder Clinical Trials
- 4.12 Anti-Heroin/Fentanyl Vaccine for Opioid Use Disorder Drug Details
 - 4.12.1 Anti-Heroin/Fentanyl Vaccine for Opioid Use Disorder Current Status
 - 4.12.2 Anti-Heroin/Fentanyl Vaccine for Opioid Use Disorder Drug Overview
 - 4.12.3 Anti-Heroin/Fentanyl Vaccine for Opioid Use Disorder Mechanism of Action
 - 4.12.4 Anti-Heroin/Fentanyl Vaccine for Opioid Use Disorder Licensing/Collaboration Companies
 - 4.12.5 Anti-Heroin/Fentanyl Vaccine for Opioid Use Disorder Clinical Trials
- 4.13 DLP-160 (naltrexone) Drug Details
 - 4.13.1 DLP-160 (naltrexone) Current Status
 - 4.13.2 DLP-160 (naltrexone) Drug Overview
 - 4.13.3 DLP-160 (naltrexone) Mechanism of Action
 - 4.13.4 DLP-160 (naltrexone) Licensing/Collaboration Companies
 - 4.13.5 DLP-160 (naltrexone) Clinical Trials
- 4.14 NB 2111 Drug Details
 - 4.14.1 NB 2111 Current Status
 - 4.14.2 NB 2111 Drug Overview
 - 4.14.3 NB 2111 Mechanism of Action
 - 4.14.4 NB 2111 Licensing/Collaboration Companies
 - 4.14.5 NB 2111 Clinical Trials
- 4.15 INDV-6200 (buprenorphine) Drug Details
 - 4.15.1 INDV-6200 (buprenorphine) Current Status
 - 4.15.2 INDV-6200 (buprenorphine) Drug Overview
 - 4.15.3 INDV-6200 (buprenorphine) Mechanism of Action
 - 4.15.4 INDV-6200 (buprenorphine) Licensing/Collaboration Companies
 - 4.15.5 INDV-6200 (buprenorphine) Clinical Trials
- 4.16 Buprenorphine/naloxone -Insys Drug Details
 - 4.16.1 Buprenorphine/naloxone -Insys Current Status
 - 4.16.2 Buprenorphine/naloxone -Insys Drug Overview
 - 4.16.3 Buprenorphine/naloxone -Insys Mechanism of Action
 - 4.16.4 Buprenorphine/naloxone -Insys Licensing/Collaboration Companies
 - 4.16.5 Buprenorphine/naloxone -Insys Clinical Trials
- 4.17 buprenorphine (BnoX) Drug Details
 - 4.17.1 buprenorphine (BnoX) Current Status
 - 4.17.2 buprenorphine (BnoX) Drug Overview
 - 4.17.3 buprenorphine (BnoX) Mechanism of Action
 - 4.17.4 buprenorphine (BnoX) Licensing/Collaboration Companies

- 4.17.5 buprenorphine (BnoX) Clinical Trials
- 4.18 18-MC Drug Details
 - 4.18.1 18-MC Current Status
 - 4.18.2 18-MC Drug Overview
 - 4.18.3 18-MC Mechanism of Action
 - 4.18.4 18-MC Licensing/Collaboration Companies
 - 4.18.5 18-MC Clinical Trials
- 4.19 NRS-033 Drug Details
 - 4.19.1 NRS-033 Current Status
 - 4.19.2 NRS-033 Drug Overview
 - 4.19.3 NRS-033 Mechanism of Action
 - 4.19.4 NRS-033 Licensing/Collaboration Companies
 - 4.19.5 NRS-033 Clinical Trials
- 4.20 NRS-067 Drug Details
 - 4.20.1 NRS-067 Current Status
 - 4.20.2 NRS-067 Drug Overview
 - 4.20.3 NRS-067 Mechanism of Action
 - 4.20.4 NRS-067 Licensing/Collaboration Companies
 - 4.20.5 NRS-067 Clinical Trials
- 4.21 OMS405 Drug Details
 - 4.21.1 OMS405 Current Status
 - 4.21.2 OMS405 Drug Overview
 - 4.21.3 OMS405 Mechanism of Action
 - 4.21.4 OMS405 Licensing/Collaboration Companies
 - 4.21.5 OMS405 Clinical Trials
- 4.22 OMS527 Drug Details
 - 4.22.1 OMS527 Current Status
 - 4.22.2 OMS527 Drug Overview
 - 4.22.3 OMS527 Mechanism of Action
 - 4.22.4 OMS527 Licensing/Collaboration Companies
 - 4.22.5 OMS527 Clinical Trials
- 4.23 OPNT003 (Intranasal nalmefene) Drug Details
 - 4.23.1 OPNT003 (Intranasal nalmefene) Current Status
 - 4.23.2 OPNT003 (Intranasal nalmefene) Drug Overview
 - 4.23.3 OPNT003 (Intranasal nalmefene) Mechanism of Action
 - 4.23.4 OPNT003 (Intranasal nalmefene) Licensing/Collaboration Companies
 - 4.23.5 OPNT003 (Intranasal nalmefene) Clinical Trials
- 4.24 OPNT005 Drug Details
 - 4.24.1 OPNT005 Current Status

- 4.24.2 OPNT005 Drug Overview
- 4.24.3 OPNT005 Mechanism of Action
- 4.24.4 OPNT005 Licensing/Collaboration Companies
- 4.24.5 OPNT005 Clinical Trials
- 4.25 OPNT006 Drug Details
 - 4.25.1 OPNT006 Current Status
 - 4.25.2 OPNT006 Drug Overview
 - 4.25.3 OPNT006 Mechanism of Action
 - 4.25.4 OPNT006 Licensing/Collaboration Companies
 - 4.25.5 OPNT006 Clinical Trials
- 4.26 OREX-1019 Drug Details
 - 4.26.1 OREX-1019 Current Status
 - 4.26.2 OREX-1019 Drug Overview
 - 4.26.3 OREX-1019 Mechanism of Action
 - 4.26.4 OREX-1019 Licensing/Collaboration Companies
 - 4.26.5 OREX-1019 Clinical Trials
- 4.27 OREX-1038 Drug Details
 - 4.27.1 OREX-1038 Current Status
 - 4.27.2 OREX-1038 Drug Overview
 - 4.27.3 OREX-1038 Mechanism of Action
 - 4.27.4 OREX-1038 Licensing/Collaboration Companies
 - 4.27.5 OREX-1038 Clinical Trials
- 4.28 Arbaclofen extended release Drug Details
 - 4.28.1 Arbaclofen extended release Current Status
 - 4.28.2 Arbaclofen extended release Drug Overview
 - 4.28.3 Arbaclofen extended release Mechanism of Action
 - 4.28.4 Arbaclofen extended release Licensing/Collaboration Companies
 - 4.28.5 Arbaclofen extended release Clinical Trials
- 4.29 PF-4363467 Drug Details
 - 4.29.1 PF-4363467 Current Status
 - 4.29.2 PF-4363467 Drug Overview
 - 4.29.3 PF-4363467 Mechanism of Action
 - 4.29.4 PF-4363467 Licensing/Collaboration Companies
 - 4.29.5 PF-4363467 Clinical Trials
- 4.30 PF-5006739 Drug Details
 - 4.30.1 PF-5006739 Current Status
 - 4.30.2 PF-5006739 Drug Overview
 - 4.30.3 PF-5006739 Mechanism of Action
 - 4.30.4 PF-5006739 Licensing/Collaboration Companies

- 4.30.5 PF-5006739 Clinical Trials
- 4.31 PMZ-2123 Drug Details
 - 4.31.1 PMZ-2123 Current Status
 - 4.31.2 PMZ-2123 Drug Overview
 - 4.31.3 PMZ-2123 Mechanism of Action
 - 4.31.4 PMZ-2123 Licensing/Collaboration Companies
 - 4.31.5 PMZ-2123 Clinical Trials
- 4.32 PPL-103 Drug Details
 - 4.32.1 PPL-103 Current Status
 - 4.32.2 PPL-103 Drug Overview
 - 4.32.3 PPL-103 Mechanism of Action
 - 4.32.4 PPL-103 Licensing/Collaboration Companies
 - 4.32.5 PPL-103 Clinical Trials
- 4.33 naltrexone extended release Drug Details
 - 4.33.1 naltrexone extended release Current Status
 - 4.33.2 naltrexone extended release Drug Overview
 - 4.33.3 naltrexone extended release Mechanism of Action
 - 4.33.4 naltrexone extended release Licensing/Collaboration Companies
 - 4.33.5 naltrexone extended release Clinical Trials
- 4.34 SER-227 Drug Details
 - 4.34.1 SER-227 Current Status
 - 4.34.2 SER-227 Drug Overview
 - 4.34.3 SER-227 Mechanism of Action
 - 4.34.4 SER-227 Licensing/Collaboration Companies
 - 4.34.5 SER-227 Clinical Trials
- 4.35 nalmefene Drug Details
 - 4.35.1 nalmefene Current Status
 - 4.35.2 nalmefene Drug Overview
 - 4.35.3 nalmefene Mechanism of Action
 - 4.35.4 nalmefene Licensing/Collaboration Companies
 - 4.35.5 nalmefene Clinical Trials
- 4.36 TRV734 Drug Details
 - 4.36.1 TRV734 Current Status
 - 4.36.2 TRV734 Drug Overview
 - 4.36.3 TRV734 Mechanism of Action
 - 4.36.4 TRV734 Licensing/Collaboration Companies
 - 4.36.5 TRV734 Clinical Trials
- 4.37 TM002 Drug Details
 - 4.37.1 TM002 Current Status

- 4.37.2 TM002 Drug Overview
- 4.37.3 TM002 Mechanism of Action
- 4.37.4 TM002 Licensing/Collaboration Companies
- 4.37.5 TM002 Clinical Trials
- 4.38 naltrexone hydrochloride Drug Details
 - 4.38.1 naltrexone hydrochloride Current Status
 - 4.38.2 naltrexone hydrochloride Drug Overview
 - 4.38.3 naltrexone hydrochloride Mechanism of Action
 - 4.38.4 naltrexone hydrochloride Licensing/Collaboration Companies
 - 4.38.5 naltrexone hydrochloride Clinical Trials

5. LATEST OPIUM (OPIOID) ADDICTION PIPELINE NEWS AND DEALS

6. APPENDIX

- 6.1 Our Databases and Reports
- 6.2 Research Methodolgy

I would like to order

Product name: 2020 Opioid Addiction Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

Product link: <https://marketpublishers.com/r/2D5E7A3129B9EN.html>

Price: US\$ 1,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2D5E7A3129B9EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

